Mostrar el registro sencillo del ítem
Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection
dc.contributor.author | Funk, Anna L. | |
dc.contributor.author | Kuppermann, Nathan | |
dc.contributor.author | Florin, Todd A. | |
dc.contributor.author | Tancredi, Daniel J. | |
dc.contributor.author | Xie, Jianling | |
dc.contributor.author | Kim, Kelly | |
dc.contributor.author | Finkelstein, Yaron | |
dc.contributor.author | Neuman, Mark I. | |
dc.contributor.author | Salvadori, Marina I. | |
dc.contributor.author | Yock-Corrales, Adriana | |
dc.contributor.author | Breslin, Kristen A. | |
dc.contributor.author | Ambroggio, Lilliam | |
dc.contributor.author | Chaudhari, Pradip P. | |
dc.contributor.author | Bergmann, Kelly R. | |
dc.contributor.author | Gardiner, Michael A. | |
dc.contributor.author | Nebhrajani, Jasmine R. | |
dc.contributor.author | Campos, Carmen | |
dc.contributor.author | Ahmad, Fahd A. | |
dc.contributor.author | Sartori, Laura F. | |
dc.contributor.author | Navanandan, Nidhya | |
dc.contributor.author | Kannikeswaran, Nirupama | |
dc.contributor.author | Caperell, Kerry | |
dc.contributor.author | Morris, Claudia R. | |
dc.contributor.author | Mintegi Raso, Santiago | |
dc.contributor.author | Gangoiti, Iker | |
dc.contributor.author | Sabhaney, Vikram J. | |
dc.contributor.author | Plint, Amy C. | |
dc.contributor.author | Klassen, Terry P. | |
dc.contributor.author | Avva, Usha R. | |
dc.contributor.author | Shah, Nipam P. | |
dc.contributor.author | Dixon, Andrew C. | |
dc.contributor.author | Lunoe, Maren M. | |
dc.contributor.author | Becker, Sarah M. | |
dc.contributor.author | Rogers, Alexander J. | |
dc.contributor.author | Pavlicich, Viviana | |
dc.contributor.author | Dalziel, Stuart R. | |
dc.contributor.author | Payne, Daniel C. | |
dc.contributor.author | Malley, Richard | |
dc.contributor.author | Borland, Meredith L. | |
dc.contributor.author | Morrison, Andrea K. | |
dc.contributor.author | Bhatt, Maala | |
dc.contributor.author | Rino, Pedro B. | |
dc.contributor.author | Beneyto Ferre, Isabel | |
dc.contributor.author | Eckerle, Michelle | |
dc.contributor.author | Kam, April J. | |
dc.contributor.author | Chong, Shu-Ling | |
dc.contributor.author | Palumbo, Laura | |
dc.contributor.author | Kwok, Maria Y. | |
dc.contributor.author | Cherry, Jonathan C. | |
dc.contributor.author | Poonai, Naveen | |
dc.contributor.author | Waseem, MD; Norma-Jean Simon, MPH; | |
dc.contributor.author | Waseem, Muhammad | |
dc.contributor.author | Simon, Norma-Jean | |
dc.contributor.author | Freedman, Stephen B. | |
dc.contributor.author | Pediatric Emergency Research Network–COVID-19 Study Team | |
dc.date.accessioned | 2022-09-19T09:30:15Z | |
dc.date.available | 2022-09-19T09:30:15Z | |
dc.date.issued | 2022-06-22 | |
dc.identifier.citation | JAMA Network Open 5(7) : (2022) // Article ID e2223253 | es_ES |
dc.identifier.issn | 2574-3805 | |
dc.identifier.uri | http://hdl.handle.net/10810/57776 | |
dc.description.abstract | IMPORTANCE Little is known about the risk factors for, and the risk of, developing post-COVID-19 conditions (PCCs) among children. OBJECTIVES To estimate the proportion of SARS-CoV-2-positive children with PCCs 90 days after a positive test result, to compare this proportion with SARS-CoV-2-negative children, and to assess factors associated with PCCs. DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study, conducted in 36 emergency departments (EDs) in 8 countries between March 7, 2020, and January 20, 2021, included 1884 SARS-CoV-2-positive children who completed 90-day follow-up; 1686 of these children were frequency matched by hospitalization status, country, and recruitment date with 1701 SARS-CoV-2-negative controls. EXPOSURE SARS-CoV-2 detected via nucleic acid testing. MAIN OUTCOMES AND MEASURES Post-COVID-19 conditions, defined as any persistent, new, or recurrent health problems reported in the 90-day follow-up survey. RESULTS Of 8642 enrolled children, 2368 (27.4%) were SARS-CoV-2 positive, among whom 2365 (99.9%) had index ED visit disposition data available; among the 1884 children (79.7%) who completed follow-up, the median age was 3 years (IQR, 0-10 years) and 994 (52.8%) were boys. A total of 110 SARS-CoV-2-positive children (5.8%; 95% CI, 4.8%-7.0%) reported PCCs, including 44 of 447 children (9.8%; 95% CI, 7.4%-13.0%) hospitalized during the acute illness and 66 of 1437 children (4.6%; 95% CI, 3.6%-5.8%) not hospitalized during the acute illness (difference. 5.3%; 95% CI, 2.5%-8.5%). Among SARS-CoV-2-positive children, the most common symptom was fatigue or weakness (21 [1.1%]). Characteristics associated with reporting at least 1 PCC at 90 days included being hospitalized 48 hours or more compared with no hospitalization (adjusted odds ratio [aOR], 2.67 [95% CI, 1.63-4.38]); having 4 or more symptoms reported at the index ED visit compared with 1 to 3 symptoms (4-6 symptoms: aOR, 2.35 [95% CI, 1.28-4.31]; >= 7 symptoms: aOR, 4.59 [95% CI, 2.50 8.44]); and being 14 years of age or older compared with younger than 1 year (aOR, 2.67 [95% CI, 1.43-4.99]). SARS-CoV-2-positive children were more likely to report PCCs at 90 days compared with those who tested negative, both among those who were not hospitalized (55 of 1295 [4.2%; 95% CI, 3.2%-5.5%] vs 35 of 1321[2.7%; 95% CI, 1.9%-3.7%]; difference, 1.6% [95% CI, 0.2%-3.0%]) and those who were hospitalized (40 of 391[10.2%; 95% CI, 7.4%-13.7%] vs 19 of 380 [5.0%; 95% CI, 3.0%-7.7%]; difference, 5.2% [95% CI, 1.5%-9.1%]). In addition, SARS-CoV-2 positivity was associated with reporting PCCs 90 days after the index ED visit (aOR, 1.63 [95% CI, 1.14-2.35]), specifically systemic health problems (eg, fatigue, weakness, fever; aOR, 2.44 [95% CI, 1.19-5.00]). CONCLUSIONS AND RELEVANCE In this cohort study, SARS-CoV-2 infection was associated with reporting PCCs at 90 days in children. Guidance and follow-up are particularly necessary for hospitalized children who have numerous acute symptoms and are older. | es_ES |
dc.description.sponsorship | This studywas supported by grants from the Canadian Institutes of Health Research (operating grant: COVID-19-clinical management); the Alberta Health Services-University of Calgary-Clinical Research Fund; the Alberta Children's Hospital Research Institute; the COVID-19 Research Accelerator Funding Track (CRAFT) Program at the University of California, Davis; and the Cincinnati Children's Hospital Medical Center Division of Emergency Medicine Small Grants Program. Dr Funk is supported by the University of Calgary Eyes-High PostDoctoral Research Fund. Dr Freedman is supported by the Alberta Children's Hospital Foundation Professorship in Child Health andWellness. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | American Medical Association | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | COVID-19 | es_ES |
dc.subject | outcomes | es_ES |
dc.title | Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | This is an open access article distributed under the terms of the CC-BY License. | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794484 | es_ES |
dc.identifier.doi | 10.1001/jamanetworkopen.2022.23253 | |
dc.departamentoes | Pediatría | es_ES |
dc.departamentoeu | Pediatria | es_ES |